Kent based medical device manufacturer Bedfont Scientific has reached a new milestone after supplying its 3,000th asthma care device to the UK market. The achievement reflects continued growth in the adoption of objective testing within primary care.
The Bedfont asthma care device milestone centres on the NObreath FeNO device, which measures fractional exhaled nitric oxide to assess airway inflammation. The technology supports healthcare professionals in the diagnosis and ongoing management of asthma and is distributed in the UK by Intermedical UK.
The milestone follows Bedfont’s acquisition by French growth buyout investor Keensight Capital in October 2025. At the time of the acquisition, Keensight Capital stated its intention to accelerate Bedfont’s expansion through organic growth and acquisitions.
Jason Smith, chief executive at Bedfont, comments: “This milestone of 3,000 devices in UK primary care highlights just how rapidly objective asthma testing is advancing.
“The updated joint UK guidelines now place even greater emphasis on FeNO, echoing the global shift toward evidence-based, accessible diagnostic tools.
“We are committed to making this technology available everywhere it is needed, ensuring clinicians and patients around the world benefit from fast, non-invasive breath testing.”
Intermedical UK, Bedfont’s distribution partner, has supplied cardio respiratory diagnostic and therapy equipment for frontline care since 1997. The company has worked alongside Bedfont to expand access to FeNO testing across the UK.
Livio Gagliardi, acting managing director at Intermedical UK, added: “This is a shared success that reflects the dedication of both the Intermedical and Bedfont teams.
“Together, we have worked hard to deliver a clinically proven, accessible, and cost-effective FeNO solution that genuinely meets the needs of frontline healthcare.
“We are incredibly grateful to our customers for placing their trust in us and for recognising the value that NObreath brings to asthma diagnosis and ongoing management.
“Their commitment to improving respiratory care is what makes milestones like this possible, and we look forward to continuing this journey of innovation and impact alongside Bedfont.”
The Bedfont asthma care device milestone highlights the growing role of FeNO testing within UK healthcare, as demand increases for diagnostic tools that support evidence based respiratory care.
